NIH Continues to Support the Best Science through R01s

By Walter Schaffer and Sally Rockey NIH Continues to Support the Best Science through R01s A response to accusations that the agency is biased against senior scientists The September issue of The Scientist included an opinion piece called “NIH R01s: No Longer the Best Science” by Dr. Les Costello.1 In that article, Dr. Costello expressed concerns about NIH policies2 related to new investigators, suggesting that they offer

Written byWalter Schaffer and Sally Rockey
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The September issue of The Scientist included an opinion piece called “NIH R01s: No Longer the Best Science” by Dr. Les Costello.1 In that article, Dr. Costello expressed concerns about NIH policies2 related to new investigators, suggesting that they offer an unfair advantage for new applicants over established investigators. Because of these concerns, we felt the need to provide some context around issues associated with new investigators and why we believe the flow of new talent is essential for the maintenance of a productive scientific enterprise.

When Dr. Costello received his first traditional NIH research grant (R01) in 1963, success rates were near 58 percent3 and 35 percent of the competing R01s went to first-time recipients.4 Data published by the NIH and available on the NIH New Investigator Web site5 shows that since that time, the proportion of awards going to previously unfunded investigators has declined and the average age ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies